X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Sygnature expands capabilities with acquisition of Alderley Oncology

    SOPHiA GENETICS and AstraZeneca partner for oncology drugs development

    Regeneron, Intellia to develop CRISPR/Cas9-based treatments

    BioMed X Launches New T Cell Immunology Discovery Platform

    OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico

    Oxford Expands Biomanufacturing Real Estate Platform with Purchase, Lease Back of GMP Facility

    Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

    Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

    Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

    Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs

    Biotech Companies In China Look To Have A Global Footprint

    Altasciences announced that it is expanding its laboratory facilities in Columbia, MO.

    Receptor Location Significant For Psychedelic Drug Effect

    Neoadjuvant Nivolumab Aids In Long Term Lung Cancer Survival

    Clinical Trials Diversity- A Much To Be Explored Segment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Sygnature expands capabilities with acquisition of Alderley Oncology

    SOPHiA GENETICS and AstraZeneca partner for oncology drugs development

    Regeneron, Intellia to develop CRISPR/Cas9-based treatments

    BioMed X Launches New T Cell Immunology Discovery Platform

    OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico

    Oxford Expands Biomanufacturing Real Estate Platform with Purchase, Lease Back of GMP Facility

    Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

    Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

    Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

    Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs

    Biotech Companies In China Look To Have A Global Footprint

    Altasciences announced that it is expanding its laboratory facilities in Columbia, MO.

    Receptor Location Significant For Psychedelic Drug Effect

    Neoadjuvant Nivolumab Aids In Long Term Lung Cancer Survival

    Clinical Trials Diversity- A Much To Be Explored Segment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Oxford Expands Biomanufacturing Real Estate Platform with Purchase, Lease Back of GMP Facility

Content Team by Content Team
21st February 2023
in Drug Development, Manufacturing, Press Statements
OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico

Oxford Properties Group, a global real estate investor, asset manager and business builder, announced the purchase and long-term lease back of 92 Crowley Drive.

The asset is a 120,000 square foot state-of-the-art biomanufacturing facility under construction in the Boston life sciences submarket of Marlborough, MA.

As part of a real estate transaction with Resilience, a technology-focused biomanufacturing company, Oxford will acquire the building and lease the property back to Resilience for up to 30 years. This deal structure raises proceeds for Resilience while allowing it to conduct its day-to-day business operations with full use of the facility.

The acquisition grows Oxford’s existing North American cGMP portfolio to 1.4 million square feet with an additional development pipeline of over 1 million square feet.

“We continue to develop a robust expertise on the real estate needs of biomanufacturing and our footprint in this space is a key pillar of our investment strategy to build a global life sciences business of scale,” said Chad Remis, executive vice president, North America at Oxford. “GMP facilities are unique, highly technical assets and represent a segment of the life sciences market in which we have intentionally set out to become a market leader. Today’s acquisition strengthens our growing relationship with Resilience, and adds another state-of-the-art, income generating asset to our North American platform.”

Remis added” “Our growing relationship with Resilience is a great example of the purpose of Oxford’s life science business. By investing our capital and capabilities to own, manage and build life sciences real estate infrastructure, we can free up capital for our customers to focus on advancing their science and delivering the life changing therapeutics of tomorrow.”

“Our acquisition of 92 Crowley aligns strongly with our biomanufacturing strategy. Its proximity to our existing cGMP investments in Boston provides significant operational efficiencies,” said Christie Chen, director of investments at Oxford. “Boston continues to be an unparalleled market in terms of talent, capital and research institutions and we will continue to deliver new real estate infrastructure into the region to support its growth and position as the global leader in life science. This conviction is evidenced by three cGMP developments that we are undertaking in the Boston market to serve the growing demand for biopharmaceutical manufacturing.”

The transaction highlights Oxford’s deep conviction in biomanufacturing as an integral part of the growth of its global life sciences business. This holistic approach seeks to provide firms the complete breadth of the required and highly technical real estate infrastructure to research, develop then manufacture the life changing therapeutics of tomorrow. Oxford’s North American cGMP platform and pipeline has now grown to 12 facilities across six markets, with the largest concentration in the Boston region totaling 775,000 square feet.

Upon completion, 92 Crowley will be Resilience’s flagship facility in the US with state of the art analytical and manufacturing technology. The facility is designed with best-in-class specifications and multi-modality manufacturing capabilities, featuring dedicated manufacturing suites, with complementary office and warehouse space.

In total, Oxford’s Boston cGMP platform and pipeline spans five facilities. In addition to 92 Crowley, Oxford owns and operates 33 New York Avenue, a fully leased and fully operational 113,000 sq ft GMP facility in Framingham, MA.

Oxford’s associated development pipeline spans three assets, all nearing completion. 149 Hayes Memorial Drive (Marlborough, MA; 140,000 sq ft), 23 Sycamore Avenue (Medford, MA; 108,000 sq ft), and 172 Middlesex Turnpike (Bedford, MA; 140,000 sq ft).

 

Previous Post

Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

Next Post

BioMed X Launches New T Cell Immunology Discovery Platform

Related Posts

Sygnature expands capabilities with acquisition of Alderley Oncology
Drug Development

SOPHiA GENETICS and AstraZeneca partner for oncology drugs development

21st February 2023
Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Drug Development

BioMed X Launches New T Cell Immunology Discovery Platform

21st February 2023
Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia
Drug Development

Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

21st February 2023
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Drug Development

Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs

21st February 2023
Biotech Companies In China Look To Have A Global Footprint
Drug Development

Altasciences announced that it is expanding its laboratory facilities in Columbia, MO.

21st February 2023
Catalent  Clinical Trial
Manufacturing

Catalent Completes Expansion of Singapore Clinical Supply Facility for Increased Temperature-Controlled Capabilities

21st February 2023
Next Post
Regeneron, Intellia to develop CRISPR/Cas9-based treatments

BioMed X Launches New T Cell Immunology Discovery Platform

Latest News

Sygnature expands capabilities with acquisition of Alderley Oncology
Drug Development

SOPHiA GENETICS and AstraZeneca partner for oncology drugs development

21st February 2023
Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Drug Development

BioMed X Launches New T Cell Immunology Discovery Platform

21st February 2023
OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico
Drug Development

Oxford Expands Biomanufacturing Real Estate Platform with Purchase, Lease Back of GMP Facility

21st February 2023
Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia
Drug Development

Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

21st February 2023
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Drug Development

Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs

21st February 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In